Salsola pollen allergy immunotherapy - ALK-Abello
Alternative Names: AVANZ® Salsola; Polen de salsola kali immunotherapy- ALK-Abello; Salsola kali pollen allergy immunotherapy - ALK-Abello; Thistle pollen allergy immunotherapy - ALK-AbelloLatest Information Update: 09 Jun 2017
At a glance
- Originator ALK-Abello
- Class Allergens; Allergy immunotherapies; Antiallergics; Tree pollen allergy immunotherapies
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Allergic rhinoconjunctivitis
Most Recent Events
- 09 Jun 2017 No recent reports on development identified - Phase-II for Allergic rhinoconjunctivitis in Spain (SC)
- 01 Dec 2014 ALK-Abello completes a phase II trial in Allergic rhinoconjunctivitis (with or without asthma) in Spain (NCT02065856)
- 16 Jun 2014 ALK-Abello completes enrolment in its phase II trial for Allergic rhinoconjunctivitis (with or without asthma) in Spain (NCT02065856)